The Inflation Reduction Act could lead to higher drug prices

An unintended consequence of the Inflation Reduction Act may be higher launch prices for specialty medicines, if manufacturers raise prices to offset increases in their Medicare Part D cost-sharing.

Part D helps Medicare beneficiaries pay for self-administered prescription drugs by splitting their cost between Medicare, manufacturers, plans and patients. ...